中国新药杂志

EGFR胞外区域突变在非小细胞肺癌中的研究进展

PDF下载

费语晨 ¹^,² , 周丽梅 ² , 吕东来 ²

中国新药杂志 | 综述 2021,30(17): 1579-1583

收起

中国新药杂志 |综述 2021 , 30 (17) : 1579 -1583

EGFR胞外区域突变在非小细胞肺癌中的研究进展

全屏

费语晨¹^,², 周丽梅², 吕东来²

作者信息

¹安徽医科大学解放军临床学院，联勤保障部队第九〇一医院，合肥　230031

²中国人民解放军联勤保障部队第九〇一医院肿瘤科，安徽省肿瘤学临床重点专科实验室，合肥　230031

通讯作者:

吕东来，男，博士，副教授，主要从事肺癌及胶质瘤相关研究。E-mail：lvxunhuan@163.com。

作者简介:

费语晨，女，硕士研究生，主要从事肺癌及胶质瘤相关研究。E-mail：qq1281033624@163.com。

Research progress of EGFR extracellular domain mutation in non-small cell lung cancer

Yu-chen FEI¹^,², Li-mei ZHOU², Dong-lai LÜ²

Affiliations

¹PLA Clinical College of Anhui Medical University, The 901 Hospital of Joint Logistics Support Force of PLA, Hefei 230031, China

²Department of Oncology, The 901 Hospital of Joint Logistics Support Force of PLA/Anhui Key Clinical Specialty Laboratory of Oncology, Hefei 230031, China

出版时间: 2021-09-15

文章导航

摘要

收起

肺癌是死亡率最高的恶性肿瘤，其中以非小细胞肺癌（non-small cell lung cancer，NSCLC）为最常见的肺癌类型。研究证实表皮生长因子受体（epidermal growth factor receptor，EGFR）的突变与非小细胞肺癌的发生密不可分。针对EGFR常见突变（如19外显子的缺失突变、20外显子的插入突变及21外显子的点突变）的相关药物已应用于临床。但在部分NSCLC患者中发现存在EGFR胞外结构域的突变，这一少见突变也影响着部分患者的诊疗。本综述介绍了EGFR胞外区域突变在NSCLC中的研究进展，探索针对此类突变的有效治疗方案，期望能为存在EGFR胞外区突变的肺癌患者的诊疗提供参考。

关键词

非小细胞肺癌 / 表皮生长因子受体 / 胞外区域 / 埃克替尼

Abstract

收起

Lung cancer is the malignant tumor with the highest mortality, of which non-small cell lung cancer (NSCLC) is the most common type. Studies have confirmed that mutations of epidermal growth factor receptor (EGFR) are closely related to the development of non-small cell lung cancer. Related drugs targeting EGFR common mutations, such as deletion of exon 19, insertion of exon 20 and point mutation of exon 21, have been applied in clinical practice. However, mutations in the extracellular domain of EGFR were found in some patients with NSCLC. This rare mutation also affects the treatment of these patients. This review introduces the research progress of EGFR extracellular region mutations in non-small cell lung cancer, and explores effective treatments for such mutations, with the hope of providing a reference for the diagnosis and treatment of lung cancer patients with EGFR extracellular region mutations.

Key words

non-small cell lung cancer / epidermal growth factor receptor / extracellular domain / icotinib

引用本文

费语晨, 周丽梅, 吕东来. EGFR胞外区域突变在非小细胞肺癌中的研究进展. 中国新药杂志, 2021 , 30 (17) : 1579 -1583 .

Yu-chen FEI, Li-mei ZHOU, Dong-lai LÜ. Research progress of EGFR extracellular domain mutation in non-small cell lung cancer[J]. Chinese Journal of New Drugs, 2021 , 30 (17) : 1579 -1583 .

基金

收起

2018年安徽省自然科学基金面上项目(1808085MH267)
安徽省重点研究与开发计划面上攻关项目(202004a07020020)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.

[2]

HERBST RS, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.

[3]

贺荣芝, 刘川, 蔡婧, 等. 非小细胞肺癌EGFR、ALK、ROS1基因突变和临床病理特征分析[J]. 临床与实验病理学杂志, 2019, 35(7): 843-845.

[4]

史云舒, 李盼华, 李班班, 等. EGFR基因少见突变型非小细胞肺癌的临床特征及应用EGFR-TKIs治疗效果评价[J]. 中国肺癌杂志, 2019, 22(5): 299-305.

[5]

郭靖, 王涛, 李齐宏, 等. 人表皮生长因子受体结构域蛋白的原核表达、纯化及活性检测[J]. 生物技术通讯, 2015, 26(5): 615-618.

[6]

邹黎黎, 柯琦. 非小细胞肺癌靶向基因及其检测研究进展[J]. 四川解剖学杂志, 2020, 28(3): 196-200.

[7]

BESSMAN NJ, FREED DM, LEMMON MA. Putting together structures of epidermal growth factor receptors[J]. Curr Opin Struct Biol, 2014, 29: 95-101.

[8]

徐丽慧, 洪岸, 何贤辉. 人EGF受体胞外域cDNA克隆及其序列分析[J]. 暨南大学学报(自然科学与医学版), 2005, 26(2): 168-173, 179.

[9]

SHAO Q, ZHU WL. Ligand binding effects on the activation of the EGFR extracellular domain[J]. Phys Chem Chem Phys, 2019, 21(15): 8141-8151.

[10]

FERGUSON KM, BERGER MB, MENDROLA JM, et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization[J]. Mol Cell, 2003, 11(2): 507-517.

[11]

WALKER F, ROTHACKER J, HENDERSON C, et al. Ligand binding induces a conformational change in epidermal growth factor receptor dimers[J]. Growth Factors, 2012, 30(6): 394-409.

[12]

LU C, MI LZ, GREY MJ, et al. Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor[J]. Mol Cell Biol, 2010, 30(22): 5432-5443.

[13]

SAADEH FS, MAHFOUZ R, ASSI HI. EGFR as a clinical marker in glioblastomas and other gliomas[J]. Int J Biol Markers, 2018, 33(1): 22-32.

[14]

WONG AJ, RUPPERT JM, BIGNER SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas[J]. Proc Natl Acad Sci, 1992, 89(7): 2965-2969.

[15]

AN Z, AKSOY O, ZHENG T, et al. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies[J]. Oncogene, 2018, 37(12): 1561-1575.

[16]

GUO G, GONG K, WOHLFELD B, et al. Ligand-independent EGFR signaling[J]. Cancer Res, 2015, 75(17): 3436-3441.

[17]

MITSUDOMI T, YATABE Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer[J]. FEBS J, 2010, 277(2): 301-308.

[18]

GAN HK, CVRLJEVIC AN, JOHNS TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered[J]. Febs J, 2013, 280(21): 5350-5370.

[19]

MISEK SA, CHEN J, SCHROEDER L, et al. EGFR signals through a DOCK180-MLK3 axis to drive glioblastoma cell invasion[J]. Mol Cancer Res, 2017, 15(8): 1085-1095.

[20]

WANG FY, KANG CS, WANG-GOU SY, et al. EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma[J]. Cancer Lett, 2017, 384: 9-18.

[21]

CHANG L, ZHAO D, LIU HB, et al. Activation of sonic hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma[J]. Mol Med Rep, 2015, 12(5): 6702-6710.

[22]

LAMMERING G, HEWIT TH, VALERIE K, et al. EGFRvIII-mediated radioresistance through a strong cytoprotective response[J]. Oncogene, 2003, 22(36): 5545-5553.

[23]

LEE JC, VIVANCO I, BEROUKHIM R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain[J]. PLoS Med, 2006, 3(12): e485.

[24]

BINDER ZA, THORNE AH, BAKAS S, et al. Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development[J]. Cancer Cell, 2018, 34(1): 163-177.e7.

[25]

LONGO SL, PADALINO DJ, MCGILLIS S, et al. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models[J]. Invest New Drugs, 2012, 30(6): 2161-2172.

[26]

LOHINAI Z, HODA MA, FABIAN K, et al. Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma[J]. J Thorac Oncol, 2015, 10(5): 738-746.

[27]

SHI Y, AU JS, THONGPRASERT S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014, 9(2): 154-162.

[28]

GUO R, GU D, ZHAO J. EGFR extracellular domain mutation in patients with lung cancer[J]. J Clin Oncol, 2019, 37(Suppl): e20532.

[29]

YU S, ZHANG Y, PAN Y, et al. The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive[J]. Onco Targets Ther, 2017, 10: 4507-4515.

[30]

DAI LM, SU XJ, LU L, et al. Nonsmall cell lung cancer with rare exon 7 p. A289V mutation in the EGFR gene responds to Icotinib treatment[J]. Medicine, 2018, 97(51): e13809.

[31]

WANG WX, XU CW, CHEN Y, et al. An EGFR extracellular domain mutation data in the East Asian non-small cell lung cancer populations and response to icotinib: a multicenter study[J]. J Clin Oncol, 2019, 37(Suppl 15): e13000.

[32]

祝冰晶, 钱娟娟, 李敬杰, 等. 厄洛替尼治疗携带EGFR A289V突变的晚期非小细胞肺鳞癌患者1例并文献复习[J]. 肿瘤综合治疗电子杂志, 2020, 6(3): 113-117.

[33]

LEI L, WANG WX, ZHU YC, et al. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: a multi-center study[J]. Cancer Sci, 2020, 111(2): 679-686.

[34]

KOHSAKA S, NAGANO M, UENO T, et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer[J]. Sci Transl Med, 2017, 9(416): eaan6566.

[35]

CHAGOYA G, KWATRA SG, NANNI CW, et al. Efficacy of osimertinib against EGFRvIII+ glioblastoma[J]. Oncotarget, 2020, 11(22): 2074-2082.

[36]

FUKAI JY, NISHIO K, ITAKURA T, et al. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III[J]. Cancer Sci, 2008, 99(10): 2062-2069.

[37]

REARDON DA, LASSMAN AB, VAN DEN BENT M, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma[J]. Neuro Oncol, 2017, 19(7): 965-975.

[38]

CHONG DQ, TOH XY, HO IA, et al. Combined treatment of nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status[J]. BMC Cancer, 2015, 15: 255.

2021年第30卷第17期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-09-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-05-18

基金

2018年安徽省自然科学基金面上项目(1808085MH267)

安徽省重点研究与开发计划面上攻关项目(202004a07020020)

作者信息

¹安徽医科大学解放军临床学院，联勤保障部队第九〇一医院，合肥　230031

²中国人民解放军联勤保障部队第九〇一医院肿瘤科，安徽省肿瘤学临床重点专科实验室，合肥　230031

通讯作者:

吕东来，男，博士，副教授，主要从事肺癌及胶质瘤相关研究。E-mail：lvxunhuan@163.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322180254374937166

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT